These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

669 related articles for article (PubMed ID: 2479463)

  • 1. Induction of lymphokine-activated killer activity by interleukin 4 in human lymphocytes preactivated by interleukin 2 in vivo or in vitro.
    Higuchi CM; Thompson JA; Lindgren CG; Gillis S; Widmer MB; Kern DE; Fefer A
    Cancer Res; 1989 Dec; 49(23):6487-92. PubMed ID: 2479463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lymphokine-activated killer function following autologous bone marrow transplantation for refractory hematological malignancies.
    Higuchi CM; Thompson JA; Cox T; Lindgren CG; Buckner CD; Fefer A
    Cancer Res; 1989 Oct; 49(20):5509-13. PubMed ID: 2477142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of interleukin 4 upon human tumoricidal cells obtained from patients bearing solid tumors.
    Jadus MR; Good RW; Crumpacker DB; Yannelli JR
    J Leukoc Biol; 1991 Feb; 49(2):139-51. PubMed ID: 1991997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of lymphokine-activated killer activity in T-replete and T-cell-depleted human bone marrow by interleukin 4.
    Drobyski WR; LeFever AV; Truitt RL
    Exp Hematol; 1991 Oct; 19(9):950-7. PubMed ID: 1716592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lymphokine-activated killer activity induced by in vivo interleukin 2 therapy: predominant role for lymphocytes with increased expression of CD2 and leu19 antigens but negative expression of CD16 antigens.
    Weil-Hillman G; Fisch P; Prieve AF; Sosman JA; Hank JA; Sondel PM
    Cancer Res; 1989 Jul; 49(13):3680-8. PubMed ID: 2471587
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulation of lymphokine release and cytolytic activities by activating peripheral blood lymphocytes via CD2.
    Valentin H; Groux H; Gelin C; Chretien I; Bernard A
    J Immunol; 1990 Feb; 144(3):875-82. PubMed ID: 1967277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction by interleukin-7 of lymphokine-activated killer activity in lymphocytes from autologous and syngeneic marrow transplant recipients before and after systemic interleukin-2 therapy.
    Pavletic Z; Benyunes MC; Thompson JA; Lindgren CG; Massumoto C; Alderson MR; Buckner CD; Fefer A
    Exp Hematol; 1993 Sep; 21(10):1371-8. PubMed ID: 8359237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin-2 modulates the expression of lymphocyte function-associated antigen-one (LFA-1) and p150,95 during the generation of lymphokine-activated killer (LAK) cells.
    Grant AJ; Merchant RE; Hall RE
    Immunology; 1989 Jan; 66(1):117-24. PubMed ID: 15493273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IL-4 inhibits IL-2 induction of LAK cytotoxicity in lymphocytes from a variety of lymphoid tissues.
    Colquhoun SD; Economou JS; Shau H; Golub SH
    J Surg Res; 1993 Nov; 55(5):486-92. PubMed ID: 8231167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generation of lymphokine-activated killer cell activity by low-dose recombinant interleukin-2 and tumor cells.
    Yamamoto S; Hoon DS; Chandler P; Schmid I; Irie RF
    Cell Immunol; 1990 Jul; 128(2):516-27. PubMed ID: 1972659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NK and LAK activities from human marrow progenitors. I. The effects of interleukin-2 and interleukin-1.
    Keever CA; Pekle K; Gazzola MV; Collins NH; Gillio A
    Cell Immunol; 1990 Mar; 126(1):211-26. PubMed ID: 1689220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification and selection of human lymphokine activated killer cell effectors and novel recycling intermediates by unique light-scattering properties.
    Loudon WG; Abraham SR; Owen-Schaub LB; Hemingway LL; Hemstreet GP; DeBault LE
    Cancer Res; 1988 Apr; 48(8):2184-92. PubMed ID: 3258186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term cultures of human peripheral blood lymphocytes with recombinant human interleukin-2 generate a population of virtually pure CD3+ CD16- CD56- large granular lymphocyte LAK cells.
    Roussel E; Gerrard JM; Greenberg AH
    Clin Exp Immunol; 1990 Nov; 82(2):416-21. PubMed ID: 1700746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin 7 enhances cytolytic T lymphocyte generation and induces lymphokine-activated killer cells from human peripheral blood.
    Alderson MR; Sassenfeld HM; Widmer MB
    J Exp Med; 1990 Aug; 172(2):577-87. PubMed ID: 2142722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of a novel CD56- lymphokine-activated killer cell precursor in cancer patients receiving recombinant interleukin 2.
    McKenzie RS; Simms PE; Helfrich BA; Fisher RI; Ellis TM
    Cancer Res; 1992 Nov; 52(22):6318-22. PubMed ID: 1384959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The effect of corticosteroid on lymphokine-activated killer (LAK) activity and the change of membrane antigen phenotype on PBMC after IL2 incubation with reference to the evaluation in vitro].
    Yoshimura A
    Nihon Ika Daigaku Zasshi; 1990 Jun; 57(3):211-21. PubMed ID: 2376610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of lymphokine-activated killer (LAK) activity in canine lymphocytes with low dose human recombinant interleukin-2 in vitro.
    Helfand SC; Soergel SA; Modiano JF; Hank JA; Sondel PM
    Cancer Biother; 1994; 9(3):237-44. PubMed ID: 7820185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natural killer and lymphokine-activated killer activities in stomach cancer patients with special emphasis on the effect of 5-fluorouracil, adriamycin and mitomycin-C chemotherapy.
    Hong WS; Kim CM; Lee JO; Kang TW; Yun TK; Kim CY
    Jpn J Clin Oncol; 1990 Mar; 20(1):87-93. PubMed ID: 2108272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interactive effects of alpha-interferon A/D and interleukin 2 on murine lymphokine-activated killer activity: analysis at the effector and precursor level.
    Chikkala NF; Lewis I; Ulchaker J; Stanley J; Tubbs R; Finke JH
    Cancer Res; 1990 Feb; 50(4):1176-82. PubMed ID: 2297766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lymphokine-activated killer activity in long-term cultures with anti-CD3 plus interleukin 2: identification and isolation of effector subsets.
    Ochoa AC; Hasz DE; Rezonzew R; Anderson PM; Bach FH
    Cancer Res; 1989 Feb; 49(4):963-8. PubMed ID: 2521457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.